myocardin-induced smooth muscle lncRNA, inducer of differentiationGenealiases: []
Q-omics provides the consensus-scored MYOSLID profile across patient tissues and cancer cell-line models. MYOSLID expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MYOSLID is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MYOSLID RNA expression shows 15,584 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where MYOSLID shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYOSLID — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYOSLID survival associations across molecular data types. MYOSLID RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYOSLID RNA expression–survival associations across cancer types. High MYOSLID expression shows unfavorable associations in HNSC, KIRP, MESO, LGG, KIRC and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MYOSLID RNA expression.
This table summarizes MYOSLID tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MYOSLID. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYOSLID shows lower tumor expression in BRCA and higher tumor expression in HNSC, LUAD, LUSC, KIRC and COAD. The HNSC box plot shows higher MYOSLID RNA expression in tumor versus normal tissue (log2 FC = +2.381, t-test p < 0.001).
This table shows molecular features associated with MYOSLID in patient tissues and cancer cell lines. In patient samples, MYOSLID shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
